Stay always up-to-date
with our corporate news

Ypsomed supplies Bigfoot Biomedical with infusion sets

Burgdorf, 24.10.2017, 7.00 a.m. – Ypsomed and the US Bigfoot Biomedical company today announced their agreement for a partnership. Ypsomed will supply Bigfoot Biomedical with a modified, patented version of the Orbit infusion set. This will be used by Bigfoot in their clinical study on automated insulin therapy in people with diabetes.


Based in California, Bigfoot Biomedical develops novel technologies for the automation of insulin therapies with a focus on everyday suitability and simple operation for the users of its products, same as Ypsomed. Bigfoot Biomedical decided in favour of Ypsomed's Orbit infusion set for the significant study of its insulin pump system. "The Orbit infusion sets are extremely well thought out. By offering our study participants an infusion set which is flexible, reliable and easy to use, we can significantly reduce the burden of diabetes therapy" is how Jeffrey Brewer, President and CEO of Bigfoot Biomedical, describes the new partnership.

"Both Ypsomed and Bigfoot Biomedical are dedicated to the development of products which simplify the everyday management of diabetes for those affected. Our partnership is an example of how consistently both companies follow this objective" says Simon Michel, CEO of Ypsomed. "This cooperation gives us the opportunity of offering our popular Orbitinfusion sets to even more people with diabetes."

The Ypsomed Orbit infusion sets can be rotated through 360° and give the users greater freedom of movement. Furthermore, they are easy to place and are fitted with a heat-activated patch for secure adhesion to the skin. TheOrbit infusion sets are available with steel or soft cannulas, depending on the preferences of the user. Ypsomed will also provide Bigfoot Biomedical with a handy inserter for their study.

Bigfoot Biomedical completed its first clinical study for their new automated solution for insulin delivery at the end of 2016 and plans to start the pivotal study with the Orbit infusion sets in 2018 in the United States.

For further information, please contact Thomas Kutt, Head of Investor Relations at Ypsomed Holding AG, at the telephone number +41 34 424 35 55 or by e-mail (thomas.kutt@ypsomed.com).

Contact:
Thomas Kutt
Head of Investor Relations
Ypsomed Holding AG
Phone +41 34 424 35 55
Send email

Go back